Hepatitis C – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hepatitis C – Pipeline Review, H1 2017’, provides an overview of the Hepatitis C pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hepatitis C

– The report reviews pipeline therapeutics for Hepatitis C by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hepatitis C therapeutics and enlists all their major and minor projects

– The report assesses Hepatitis C therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hepatitis C

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hepatitis C

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

AbbVie Inc

AIMM Therapeutics BV

Akshaya Bio Inc

Amarillo Biosciences Inc

Amarna Therapeutics BV

ARA Healthcare Pvt Ltd

Aviragen Therapeutics Inc

Beijing Kawin Technology Share-Holding Co Ltd

Beta Pharma Inc

Biocad

Biotest Pharmaceuticals Corp

Biotron Ltd

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Bristol-Myers Squibb Company

Cocrystal Pharma Inc

Conatus Pharmaceuticals Inc

ContraVir Pharmaceuticals Inc

DEKK-TEC Inc

Delpor Inc

F. Hoffmann-La Roche Ltd

Formune SL

Genecode AS

GeneCure LLC

Gilead Sciences Inc

GinkgoPharma Co Ltd

GlaxoSmithKline Plc

HanAll Biopharma Co Ltd

ImmunoBiology Ltd

ImmunoClin Corp

Immunotope Inc

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

JN-International Medical Corp

Johnson & Johnson

Karyopharm Therapeutics Inc

Kineta Inc

Ligand Pharmaceuticals Inc

Medivir AB

Merck & Co Inc

Microbio Co Ltd

Microbiotix Inc

MultiCell Technologies Inc

NeuroVive Pharmaceutical AB

Novalex Therapeutics Inc

Novartis AG

NovaTarg Therapeutics Inc

Ono Pharmaceutical Co Ltd

Pfenex Inc

Pfizer Inc

PharmaEssentia Corp

Presidio Pharmaceuticals Inc

Profectus BioSciences Inc

Replicor Inc

Rodos BioTarget GmbH

Solon Eiendom ASA

SomaGenics Inc

Sorrento Therapeutics Inc

Sudershan Biotech Ltd

TaiGen Biotechnology Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Therapure Biopharma Inc

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Vakzine Projekt Management GmbH

Vertex Pharmaceuticals Inc

WhanIn Pharmaceutical Co Ltd

Zylacta Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Hepatitis C - Overview 7

Hepatitis C - Therapeutics Development 8

Hepatitis C - Therapeutics Assessment 29

Hepatitis C - Companies Involved in Therapeutics Development 39

Hepatitis C - Drug Profiles 74

Hepatitis C - Dormant Projects 388

Hepatitis C - Discontinued Products 405

Hepatitis C - Product Development Milestones 410

Appendix 424

List of Tables

List of Tables

Number of Products under Development for Hepatitis C, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hepatitis C – Pipeline by 3-V Biosciences Inc, H1 2017

Hepatitis C – Pipeline by AbbVie Inc, H1 2017

Hepatitis C – Pipeline by AIMM Therapeutics BV, H1 2017

Hepatitis C – Pipeline by Akshaya Bio Inc, H1 2017

Hepatitis C – Pipeline by Amarillo Biosciences Inc, H1 2017

Hepatitis C – Pipeline by Amarna Therapeutics BV, H1 2017

Hepatitis C – Pipeline by ARA Healthcare Pvt Ltd, H1 2017

Hepatitis C – Pipeline by Aviragen Therapeutics Inc, H1 2017

Hepatitis C – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017

Hepatitis C – Pipeline by Beta Pharma Inc, H1 2017

Hepatitis C – Pipeline by Biocad, H1 2017

Hepatitis C – Pipeline by Biotest Pharmaceuticals Corp, H1 2017

Hepatitis C – Pipeline by Biotron Ltd, H1 2017

Hepatitis C – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Hepatitis C – Pipeline by Bolder Biotechnology Inc, H1 2017

Hepatitis C – Pipeline by Bristol-Myers Squibb Company, H1 2017

Hepatitis C – Pipeline by Cocrystal Pharma Inc, H1 2017

Hepatitis C – Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Hepatitis C – Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Hepatitis C – Pipeline by DEKK-TEC Inc, H1 2017

Hepatitis C – Pipeline by Delpor Inc, H1 2017

Hepatitis C – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hepatitis C – Pipeline by Formune SL, H1 2017

Hepatitis C – Pipeline by Genecode AS, H1 2017

Hepatitis C – Pipeline by GeneCure LLC, H1 2017

Hepatitis C – Pipeline by Gilead Sciences Inc, H1 2017

Hepatitis C – Pipeline by GinkgoPharma Co Ltd, H1 2017

Hepatitis C – Pipeline by GlaxoSmithKline Plc, H1 2017

Hepatitis C – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Hepatitis C – Pipeline by ImmunoBiology Ltd, H1 2017

Hepatitis C – Pipeline by ImmunoClin Corp, H1 2017

Hepatitis C – Pipeline by Immunotope Inc, H1 2017

Hepatitis C – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Hepatitis C – Pipeline by Integrated BioTherapeutics Inc, H1 2017

Hepatitis C – Pipeline by JN-International Medical Corp, H1 2017

Hepatitis C – Pipeline by Johnson & Johnson, H1 2017

Hepatitis C – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Hepatitis C – Pipeline by Kineta Inc, H1 2017

Hepatitis C – Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Hepatitis C – Pipeline by Medivir AB, H1 2017

Hepatitis C – Pipeline by Merck & Co Inc, H1 2017

Hepatitis C – Pipeline by Microbio Co Ltd, H1 2017

Hepatitis C – Pipeline by Microbiotix Inc, H1 2017

Hepatitis C – Pipeline by MultiCell Technologies Inc, H1 2017

Hepatitis C – Pipeline by NeuroVive Pharmaceutical AB, H1 2017

Hepatitis C – Pipeline by Novalex Therapeutics Inc, H1 2017

Hepatitis C – Pipeline by Novartis AG, H1 2017

Hepatitis C – Pipeline by NovaTarg Therapeutics Inc, H1 2017

Hepatitis C – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Hepatitis C – Pipeline by Pfenex Inc, H1 2017

Hepatitis C – Pipeline by Pfizer Inc, H1 2017

Hepatitis C – Pipeline by PharmaEssentia Corp, H1 2017

Hepatitis C – Pipeline by Presidio Pharmaceuticals Inc, H1 2017

Hepatitis C – Pipeline by Profectus BioSciences Inc, H1 2017

Hepatitis C – Pipeline by Replicor Inc, H1 2017

Hepatitis C – Pipeline by Rodos BioTarget GmbH, H1 2017

Hepatitis C – Pipeline by Solon Eiendom ASA, H1 2017

Hepatitis C – Pipeline by SomaGenics Inc, H1 2017

Hepatitis C – Pipeline by Sorrento Therapeutics Inc, H1 2017

Hepatitis C – Pipeline by Sudershan Biotech Ltd, H1 2017

Hepatitis C – Pipeline by TaiGen Biotechnology Co Ltd, H1 2017

Hepatitis C – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017

Hepatitis C – Pipeline by Therapure Biopharma Inc, H1 2017

Hepatitis C – Pipeline by Theravectys SA, H1 2017

Hepatitis C – Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017

Hepatitis C – Pipeline by Vakzine Projekt Management GmbH, H1 2017

Hepatitis C – Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Hepatitis C – Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017

Hepatitis C – Pipeline by Zylacta Corp, H1 2017

Hepatitis C – Dormant Projects, H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..1), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..2), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..3), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..4), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..5), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..6), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..7), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..8), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..9), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..10), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..11), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..12), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..13), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..14), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..15), H1 2017

Hepatitis C – Dormant Projects, H1 2017 (Contd..16), H1 2017

Hepatitis C – Discontinued Products, H1 2017

Hepatitis C – Discontinued Products, H1 2017 (Contd..1), H1 2017

Hepatitis C – Discontinued Products, H1 2017 (Contd..2), H1 2017

Hepatitis C – Discontinued Products, H1 2017 (Contd..3), H1 2017

Hepatitis C – Discontinued Products, H1 2017 (Contd..4), H1 2017

List of Figures

List of Figures

Number of Products under Development for Hepatitis C, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports